AstraZeneca has submitted a request to the US FDA for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. AZD7442 is a combination cocktail of tixagevimab and cilgavimab, both originating from B-cells donated by patients who recovered from COVID-19. AZD7442 is intended to provide protection for individuals not expected to mount an adequate immune response following vaccination, including the immunocompromised or elderly.
AstraZeneca recently presented data from the phase 3 PROVENT trial and the phase 3 STORM CHASER trial.
The randomized, double-blind, placebo-controlled, multi-center PROVENT trial assessed the safety and efficacy of a single 300mg dose of AZD7442 compared to placebo for the prevention of COVID-19 in 5,197 subjects. AZD7442 reduced the risk of developing symptomatic COVID-19 by 77%, compared to placebo. Over 75% of participants in PROVENT presented with co-morbidities associated with an increased risk of severe disease or a reduced immune response to vaccination. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. There were no cases of severe COVID-19 ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).